Roche i Norge

Roche’s Perjeta significantly extends survival in people with HER2-positive metastatic breast cancer

Roche reports positive studies of MabThera given by subcutaneous injection

Roche receives positive opinion from European Medicines Agency for Avastin treatment beyond first progression in people with advanced colorectal cancer

Roche medicine Avastin receives EU approval for the treatment of women with recurrent, platinum-sensitive ovarian cancer

Roche’s trastuzumab emtansine (T-DM1) significantly extended survival in people with aggressive form of breast cancer

Final analysis of Phase III HERA trial confirmed one year of Herceptin treatment as standard of care in early-stage HER2-positive breast cancer

Roche’s targeted investigational breast cancer medicine, trastuzumab emtansine (T-DM1), reduced the risk of cancer worsening or death by 35 percent in pivotal phase III trial

Roche study showed that adding Avastin to chemotherapy cut the risk of the disease getting worse in difficult-to-treat recurrent ovarian cancer by half